PL2044199T3 - Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej - Google Patents
Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowejInfo
- Publication number
- PL2044199T3 PL2044199T3 PL07810511T PL07810511T PL2044199T3 PL 2044199 T3 PL2044199 T3 PL 2044199T3 PL 07810511 T PL07810511 T PL 07810511T PL 07810511 T PL07810511 T PL 07810511T PL 2044199 T3 PL2044199 T3 PL 2044199T3
- Authority
- PL
- Poland
- Prior art keywords
- serca2a
- adeno
- extended
- gene therapy
- viral vectors
- Prior art date
Links
- 238000001415 gene therapy Methods 0.000 title 1
- 238000001802 infusion Methods 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83332406P | 2006-07-25 | 2006-07-25 | |
PCT/US2007/016129 WO2008013692A2 (en) | 2006-07-25 | 2007-07-16 | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy |
EP07810511A EP2044199B1 (en) | 2006-07-25 | 2007-07-16 | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors comprising serca2a for gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2044199T3 true PL2044199T3 (pl) | 2013-04-30 |
Family
ID=38581949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL07810511T PL2044199T3 (pl) | 2006-07-25 | 2007-07-16 | Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej |
Country Status (13)
Country | Link |
---|---|
US (2) | US20080076730A1 (pl) |
EP (2) | EP2460879A1 (pl) |
JP (2) | JP5623740B2 (pl) |
KR (1) | KR20090035711A (pl) |
CN (1) | CN101495627A (pl) |
AU (1) | AU2007277392A1 (pl) |
CA (1) | CA2658628A1 (pl) |
DK (1) | DK2044199T3 (pl) |
ES (1) | ES2398593T3 (pl) |
GB (1) | GB2437893A (pl) |
IL (1) | IL196541A (pl) |
PL (1) | PL2044199T3 (pl) |
WO (1) | WO2008013692A2 (pl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2244740A1 (en) | 2008-02-19 | 2010-11-03 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
WO2011084964A1 (en) * | 2010-01-05 | 2011-07-14 | Celladon Corporation | Methods for increasing expression of serca2a in cardiac muscle |
WO2017184613A1 (en) * | 2016-04-18 | 2017-10-26 | Eiger Biopharmaceuticals, Inc. | Methods and compositions for consistent intracoronary administration of a biologic |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
US5587308A (en) * | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US6268213B1 (en) * | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5478745A (en) * | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5658785A (en) * | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US6613749B1 (en) | 1994-07-26 | 2003-09-02 | Imperial College Innovations Limited | Papovavirus pseudocapsids and use thereof for exogenous material transfer |
WO2001034208A1 (en) * | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
US7745416B2 (en) * | 1995-04-11 | 2010-06-29 | The Regents Of The University Of California | Method for in vivo regulation of cardiac muscle contractility |
US5773289A (en) * | 1995-06-06 | 1998-06-30 | University Of Pittsburgh | AAV directed targeted integration |
US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
US6162796A (en) * | 1995-09-27 | 2000-12-19 | The Rockefeller University | Method for transferring genes to the heart using AAV vectors |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
JP2000500744A (ja) | 1995-11-09 | 2000-01-25 | マイクロバイオロジカル リサーチ オーソリティー | ワクチン接種および遺伝子治療のためのマイクロカプセル化dna |
US20020001574A1 (en) | 1995-12-13 | 2002-01-03 | Jon A. Woiff | Process of delivering a polynucleotide to a muscle cell via the vascular system |
US5858351A (en) * | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US5846528A (en) * | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
US5962313A (en) * | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
US20090239940A1 (en) * | 1997-07-22 | 2009-09-24 | Del Monte Federica | Treating heart failure and ventricular arrhythmias |
US20050095227A1 (en) * | 1997-07-22 | 2005-05-05 | The General Hospital Corporation | Treating heart failure |
US6566118B1 (en) * | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6410300B1 (en) * | 1998-01-12 | 2002-06-25 | The University Of North Carolina At Chapel Hill | Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV |
CN101186928A (zh) * | 1998-02-11 | 2008-05-28 | 加利福尼亚大学董事会 | 核酸和血管活性剂相组合用于加强的基因投递 |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
US6759237B1 (en) * | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
WO2000038518A1 (en) | 1998-12-28 | 2000-07-06 | Arch Development Corporation | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US20020045264A1 (en) * | 2000-03-14 | 2002-04-18 | During Matthew J. | Production of chimeric capsid vectors |
US20020106381A1 (en) * | 2000-06-13 | 2002-08-08 | High Katherine A. | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
AU8880701A (en) * | 2000-09-06 | 2002-03-22 | Univ Johns Hopkins | Cardiac arrhythmia treatment methods |
EP1317289B1 (en) * | 2000-09-11 | 2009-02-25 | The Regents of the University of California | Dominant negative PLB mutant for use in treating cardiac disease |
NZ600121A (en) * | 2001-11-13 | 2013-12-20 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
US20040106954A1 (en) * | 2002-11-15 | 2004-06-03 | Whitehurst Todd K. | Treatment of congestive heart failure |
US7781415B2 (en) * | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
DE602004006272T2 (de) * | 2003-07-17 | 2008-01-10 | Bayerische Julius-Maximilians-Universität Würzburg | Verwendung von fak verwandten nicht kinase zur herstellung eines medikaments zur inhibierung der stenose und restnose |
US7291604B2 (en) * | 2003-09-03 | 2007-11-06 | The General Hospital Corporation | Methods of treating restenosis |
EP1691609A4 (en) * | 2003-12-11 | 2006-11-29 | Mirus Bio Corp | RELEASE OF VIRUS VECTORS ANEXTRAVASAL PARENCHYM CELLS |
US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
EP1791432A4 (en) * | 2004-09-09 | 2010-07-07 | Gen Hospital Corp | MODULATION OF PHOSPHATASE ACTIVITY IN CARDIAC CELLS |
WO2006089340A2 (en) * | 2005-02-23 | 2006-08-31 | V-Kardia Pty Ltd | Polynucleotide delivery to cardiac tissue |
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
EP2244740A1 (en) * | 2008-02-19 | 2010-11-03 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
-
2007
- 2007-07-16 EP EP12151812A patent/EP2460879A1/en not_active Withdrawn
- 2007-07-16 GB GB0716413A patent/GB2437893A/en not_active Withdrawn
- 2007-07-16 KR KR1020097003514A patent/KR20090035711A/ko not_active Application Discontinuation
- 2007-07-16 EP EP07810511A patent/EP2044199B1/en not_active Not-in-force
- 2007-07-16 PL PL07810511T patent/PL2044199T3/pl unknown
- 2007-07-16 CA CA002658628A patent/CA2658628A1/en not_active Abandoned
- 2007-07-16 JP JP2009521759A patent/JP5623740B2/ja active Active
- 2007-07-16 AU AU2007277392A patent/AU2007277392A1/en not_active Abandoned
- 2007-07-16 ES ES07810511T patent/ES2398593T3/es active Active
- 2007-07-16 WO PCT/US2007/016129 patent/WO2008013692A2/en active Application Filing
- 2007-07-16 CN CNA2007800283615A patent/CN101495627A/zh active Pending
- 2007-07-16 DK DK07810511.1T patent/DK2044199T3/da active
- 2007-07-17 US US11/778,900 patent/US20080076730A1/en not_active Abandoned
-
2009
- 2009-01-15 IL IL196541A patent/IL196541A/en active IP Right Grant
-
2014
- 2014-07-31 JP JP2014156560A patent/JP2014218509A/ja active Pending
-
2016
- 2016-10-13 US US15/292,642 patent/US20170252462A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2008013692A2 (en) | 2008-01-31 |
GB0716413D0 (en) | 2007-10-03 |
US20170252462A1 (en) | 2017-09-07 |
CA2658628A1 (en) | 2008-01-31 |
US20080076730A1 (en) | 2008-03-27 |
EP2460879A1 (en) | 2012-06-06 |
AU2007277392A1 (en) | 2008-01-31 |
GB2437893A (en) | 2007-11-07 |
EP2044199B1 (en) | 2012-11-14 |
JP5623740B2 (ja) | 2014-11-12 |
JP2014218509A (ja) | 2014-11-20 |
IL196541A (en) | 2012-12-31 |
CN101495627A (zh) | 2009-07-29 |
WO2008013692A3 (en) | 2008-05-02 |
ES2398593T3 (es) | 2013-03-20 |
KR20090035711A (ko) | 2009-04-10 |
EP2044199A2 (en) | 2009-04-08 |
JP2009544698A (ja) | 2009-12-17 |
IL196541A0 (en) | 2009-11-18 |
DK2044199T3 (da) | 2013-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FIC20230026I1 (fi) | Etranakogeenidetsaparvoveekki (adenoassosioitu virusvektori, joka sisältää ihmisen hyytymistekijä IX:n geenin koodonioptimoitua Padua-johdannaista B-hemofilian hoitoon) | |
PL2002003T3 (pl) | Wektor genetyczny zawierający mi-RNA | |
EP1885186A4 (en) | METHOD FOR TARGETED GENETIC ABLE VIRAL VECTORS | |
EP2001517A4 (en) | REGULATED EXPRESSION OF RECOMBINANT PROTEINS FROM ADENO-ASSOCIATED VIRAL VECTORS | |
IL190114A0 (en) | Inhibition of viral gene expression using small interfering rna | |
HK1151829A1 (en) | Replication-defective arenavirus vectors | |
EP2178567A4 (en) | STABILIZED IMMUNOMODULATOR RNA COMPOUNDS (SIMRA) | |
EP2342321A4 (en) | CONSTRUCTION OF GENERATOR GUIDANCE BASED ON A COMPLETELY DELETED ADENOVIRUS AND USES THEREOF | |
EP2139416A4 (en) | BASKET CATHETER WITH SEVERAL ELECTRODES | |
EP2225002A4 (en) | RNA INTERFERENCE FOR THE TREATMENT OF CARDIAC SUFFICIENCIES | |
EP2037892A4 (en) | MODIFIED FATCOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY | |
GB2437861B (en) | Finger boot basket | |
EP1868679A4 (en) | THERAPY EXERCISING NON-IMMEDIATE EFFECTS | |
HK1135731A1 (en) | Vectors for multiple gene expression | |
DE602005027253D1 (de) | Herbizidresistenz verleihende gene | |
SI2018164T1 (sl) | Uporaba kombinacijskih pripravkov, ki obsegajo antimikotike | |
EP2187898B8 (en) | Use of viral vectors carrying the cyp46a1 gene for the treatment of alzheimer's disease | |
EP2008662A4 (en) | LIPOLYSIS PROMOTER | |
EP1928504A4 (en) | GENE THERAPY IN THE LIVER | |
PL2044199T3 (pl) | Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej | |
HK1141831A1 (en) | Vector for gene therapy | |
EP1924698A4 (en) | EYE GENE THERAPY ON THE EYE USING AVALANCHE-MEDIATED TRANSFECTION | |
GB0406728D0 (en) | Gene therapy | |
ZA200709271B (en) | abfB-2 gene of Penicillium funiculosum | |
ZA200709272B (en) | abfB-1 gene of Penicillium funiculosum |